| Phase 17 trials |
|
Phase 1
|
NCT05561673 |
Oct 2022 → Nov 2024 |
hepatitis B virus infection |
GlaxoSmithKline |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03275389 |
Sep 2017 → Mar 2020 |
influenza |
GlaxoSmithKline |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03014310 |
Jan 2017 → Dec 2018 |
avian influenza |
National Institute of Allergy and Infectious Diseases (NIAID) |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02957656 |
Dec 2016 → Jun 2018 |
— |
National Institute of Allergy and Infectious Diseases (NIAID) |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02624219 |
Aug 2016 → Jan 2018 |
avian influenza |
National Institute of Allergy and Infectious Diseases (NIAID) |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT01573312 |
May 2012 → Jan 2014 |
influenza |
National Institute of Allergy and Infectious Diseases (NIAID) |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT01317758 |
May 2011 → Sep 2012 |
influenza |
National Institute of Allergy and Infectious Diseases (NIAID) |
Completed
|
No outcome recorded
|
| Phase 1/24 trials |
|
Phase 1/2
|
NCT04959344 |
Jul 2021 → Sep 2022 |
Klebsiella infectious disease |
LimmaTech Biologics AG |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT04750343 |
Feb → Jul 2021 |
— |
SK Bioscience Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 1/2
|
NCT04622592 |
Nov 2020 → Apr 2022 |
influenza |
Medicago |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT01578317 |
Mar 2012 → Jan 2016 |
influenza |
National Institute of Allergy and Infectious Diseases (NIAID) |
Completed
|
No outcome recorded
|
| Phase 210 trials · 1 met primary |
|
Phase 2
|
NCT03738241 |
Dec 2018 → Jun 2020 |
avian influenza |
National Institute of Allergy and Infectious Diseases (NIAID) |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03589807 |
Aug 2018 → Jun 2020 |
avian influenza |
National Institute of Allergy and Infectious Diseases (NIAID) |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03497845 |
Mar 2018 → Nov 2019 |
avian influenza |
Biomedical Advanced Research and Development Authority |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03312231 |
Feb 2018 → Sep 2019 |
avian influenza |
National Institute of Allergy and Infectious Diseases (NIAID) |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03283319 |
Sep → Dec 2017 |
influenza |
Biomedical Advanced Research and Development Authority |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02921997 |
Nov 2016 → Mar 2017 |
avian influenza, swine influenza |
National Institute of Allergy and Infectious Diseases (NIAID) |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT01942265 |
Sep 2013 → Jan 2015 |
influenza |
National Institute of Allergy and Infectious Diseases (NIAID) |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT01910519 |
Jul 2013 → Feb 2015 |
avian influenza |
National Institute of Allergy and Infectious Diseases (NIAID) |
Completed
|
Met primary
|
|
Phase 2
|
NCT00963157 |
Sep 2009 → Dec 2010 |
influenza |
National Institute of Allergy and Infectious Diseases (NIAID) |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT00964951 |
? → Nov 2010 |
influenza |
National Institute of Allergy and Infectious Diseases (NIAID) |
Withdrawn
|
No outcome recorded
|
| Comparator or background therapy3 trials |
|
Phase 1
|
NCT04405908 Comparator |
Jun 2020 → Oct 2021 |
COVID-19 |
Clover Biopharmaceuticals AUS Pty |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT05289037 Background |
Mar 2022 → Nov 2023 |
COVID-19 |
National Institute of Allergy and Infectious Diseases (NIAID) |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03318315 Background |
Feb 2018 → Jul 2019 |
avian influenza |
National Institute of Allergy and Infectious Diseases (NIAID) |
Completed
|
No outcome recorded
|